Fluorodeoxyglucose positron emission tomography may aid the diagnosis of aggressive primary prostate cancer: A case series study

Bartoletti,Riccardo; Meliani,Enrico; Bongini,Andrea; Magno,Carlo; Cai,Tommaso

doi:10.3892/ol.2013.1747

2014-February Volume 7 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-February Volume 7 Issue 2

Full Size Image

Article

Fluorodeoxyglucose positron emission tomography may aid the diagnosis of aggressive primary prostate cancer: A case series study

Authors:
- Riccardo Bartoletti
- Enrico Meliani
- Andrea Bongini
- Carlo Magno
- Tommaso Cai
View Affiliations / Copyright

Affiliations: Department of Medical and Surgical Critical Care, Urology Unit, University of Florence, Florence, Italy, Urology Unit, Santa Maria Annunziata Hospital, Florence, Italy, Department of Urology, Santa Chiara Regional Hospital, Trento, Italy
Pages: 381-386
|
Published online on: December 9, 2013

https://doi.org/10.3892/ol.2013.1747
Expand metrics +

Abstract

Recent evidence has shown that positive results may be observed for fluorodeoxyglucose‑positron emission tomography (FDG‑PET) in undifferentiated, biologically aggressive and metastatic tumors. The present study describes a case series of six patients with normal prostate‑specific antigen (PSA) serum levels who underwent FDG‑PET due to other causes. Positive PET results were observed at the prostate and the patients were subsequently diagnosed with high‑risk prostate cancer. Clinical, anamnestic, laboratory and instrumental data were collected from six asymptomatic patients with total serum PSA levels of <4 ng/ml who had undergone FDG‑PET due to other causes. The FDG‑PET and prostate biopsy were positive for prostate cancer. All the patients were treated with radical intent. The median age was 66 years (range, 52‑72 years), the median total PSA value was 2.4 ng/ml (range, 1.5‑3.9 ng/ml) and the body mass index was 26.4 (range, 21.8‑30.2). Three of the six patients underwent FDG‑PET due to a clinical suspicion of multiple myeloma, while three patients were examined for other oncological diseases. The pathological analysis at the prostate biopsy revealed three patients with a Gleason score of 6, two with a score of 7 (4+3) and one with a score of 8 (4+4). Five of the six patients were treated by radical prostatectomy and one by radiotherapy. The pathological analysis revealed one patient of pT2a stage, three of pT2c and one of pT3b. No patients demonstrated lymph node invasion. The definitive Gleason score was 3+3 in one patient, 4+3 in one patient, 4+4 in two patients and 5+3 in one patient. Following a median follow‑up time of six months (range, 1‑12 months), five of the six patients underwent FDG‑PET again, which revealed negative results. At the end of this study, these patients were alive without evidence of disease. By contrast, one patient demonstrated positive FDG‑PET results. In conclusion, FDG‑PET has been used to characterize prostate cancers in patients with apparently normal PSA levels.

View Figures

View References

1	Artibani W: Landmarks in prostate cancer diagnosis: the biomarkers. BJU Int. 110(Suppl 1): S8–S13. 2012. View Article : Google Scholar
2	Wallner LP, Frencher SK, Hsu JW, et al: Changes in serum prostate-specific antigen levels and the identification of prostate cancer in a large managed care population. BJU Int. 111:1245–1252. 2013. View Article : Google Scholar
3	Ackerstaff E, Glunde K and Bhujwalla ZM: Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem. 90:525–533. 2003. View Article : Google Scholar : PubMed/NCBI
4	Kwee SA, Coel MN, Lim J and Ko JP: Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol. 173:252–255. 2005. View Article : Google Scholar : PubMed/NCBI
5	Reske SN, Blumstein NM, Neumaier B, et al: Imaging prostate cancer with 11C-choline PET/CT. J Nucl Med. 47:1249–1254. 2006.PubMed/NCBI
6	Martorana G, Schiavina R, Corti B, et al: 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. J Urol. 176:954–960. 2006. View Article : Google Scholar
7	Scher B, Seitz M, Albinger W, et al: Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 34:45–53. 2007. View Article : Google Scholar : PubMed/NCBI
8	Swartzenböck S, Souvatzoglou M and Krause BJ: Choline PET and PET/CT in primary diagnosis and staging of prostate cancer. Theranostics. 2:318–330. 2012.PubMed/NCBI
9	Minamimoto R, Senda M, Jinnouchi S, et al: The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006–2009) nationwide survey. Ann Nucl Med. 27:46–57. 2013.PubMed/NCBI
10	Thompson IM, Tangen C and Goodman P: The prostate cancer prevention trial: design, status and promise. World J Urol. 21:28–30. 2003.PubMed/NCBI
11	Schröder FH, Hugosson J, Roobol MJ, et al; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 360:1320–1328. 2009.PubMed/NCBI
12	Heijndijk EA, Wever EM, Auvinen A, et al: Quality of life effects of prostate-specific antigen screening. N Engl J Med. 367:595–605. 2012. View Article : Google Scholar : PubMed/NCBI
13	Testa C, Schiavina R, Lodi R, et al: Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology. 244:797–806. 2007. View Article : Google Scholar : PubMed/NCBI
14	Yamaguchi T, Lee J, Uemura H, et al: Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy. Eur J Nucl Med Mol Imaging. 32:742–748. 2005. View Article : Google Scholar : PubMed/NCBI
15	Hwang I, Chong A, Jung SI, et al: Is further evaluation needed for incidental focal uptake in the prostate in 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography images? Ann Nucl Med. 27:140–145. 2013. View Article : Google Scholar
16	Wright JL, Lin DW and Stanford JL: The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate. 71:1631–1637. 2011. View Article : Google Scholar : PubMed/NCBI
17	Helfand BT, Kan D, Modi P and Catalona WJ: Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a ‘normal’ prostate specific antigen and digital rectal examination. Prostate. 71:394–402. 2011.PubMed/NCBI
18	Koochekpour S, Majumdar S, Azabdaftari G, et al: Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res. 18:5888–5901. 2012. View Article : Google Scholar

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Fluorodeoxyglucose positron emission tomography may aid the diagnosis of aggressive primary prostate cancer: A case series study

This article is mentioned in:

Abstract

Figure 1

Related Articles